External broker reports(aggregated public sources), HDFC Securities

HDFC Securities

HDFC securities is the best online trading platform for stocks, IPOs, mutual fund in India. 

Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only.  Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

External broker reports(aggregated public sources)

HDFC securities is the best online trading platform for stocks, IPOs, mutual fund in India. 

Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only. Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

Equity Bottom-Up

Sun Pharmaceutical Industries / Equity Bottom-Up

<ul><li>We recently interacted with the senior management of Sun Pharma—Ms. Jayashree Satagopan, CFO, and Dr. Abhishek Sharma, Head IR.</li><li>The management highlighted (1) focus on Innovative medicines (global specialty) and India formulation growth,</li><li>(2) investment of USD 100 mn to scale up the new innovative medicine launches (Leqselvi and Unloxcyt) to see traction in the next 1-2 years</li></ul><p><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></p>

We recently interacted with the senior management of Sun Pharma—Ms. Jayashree Satagopan, CFO, and Dr. Abhishek Sharma, Head IR.The management highlighted (1) focus on Innovative medicines (global specialty) and India formulation growth,(2) investment of USD 100 mn to scale up the new innovative medicine launches (Leqselvi and Unloxcyt) to see traction in the next 1-2 yearsContent is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Sun Pharmaceutical Industries: Innovative Medicines and India Key Drivers. Maintain BUY